Full Press Release Details
Zenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab for the Treatment of Immunoglobulin G4-Related Disease (IgG4-RD).
ZBIO
Zenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab for the Treatment of Immunoglobulin G4-Related Disease (IgG4-RD)
Key Takeaway: Zenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab for the Treatment of Immunoglobulin G4-Related Disease (IgG4-RD)
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+116%
120-day peak, hindsight
Typical move
8.9%
average across 3 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Orelabrutinib
Phase 3 · Multiple Sclerosis (MS) Primary Progressive